Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury

Glia. 2005 Sep;51(4):254-65. doi: 10.1002/glia.20202.

Abstract

Erythropoietin (Epo) expresses potent neuroprotective activity in the peripheral nervous system; however, the underlying mechanism remains incompletely understood. In this study, we demonstrate that Epo is upregulated in sciatic nerve after chronic constriction injury (CCI) and crush injury in rats, largely due to local Schwann cell production. In uninjured and injured nerves, Schwann cells also express Epo receptor (EpoR), and its expression is increased during Wallerian degeneration. CCI increased the number of Schwann cells at the injury site and the number was further increased by exogenously administered recombinant human Epo (rhEpo). To explore the activity of Epo in Schwann cells, primary cultures were established. These cells expressed cell-surface Epo receptors, with masses of 71 and 62 kDa, as determined by surface protein biotinylation and affinity precipitation. The 71-kDa species was rapidly but transiently tyrosine-phosphorylated in response to rhEpo. ERK/MAP kinase was also activated in rhEpo-treated Schwann cells; this response was blocked by pharmacologic antagonism of JAK-2. RhEpo promoted Schwann cell proliferation, as determined by BrdU incorporation. Cell proliferation was ERK/MAP kinase-dependent. These results support a model in which Schwann cells are a major target for Epo in injured peripheral nerves, perhaps within the context of an autocrine signaling pathway. EpoR-induced cell signaling and Schwann cell proliferation may protect injured peripheral nerves and promote regeneration.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Autocrine Communication / drug effects
  • Autocrine Communication / physiology
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Disease Models, Animal
  • Erythropoietin / pharmacology*
  • Erythropoietin / therapeutic use
  • Extracellular Signal-Regulated MAP Kinases / drug effects
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Female
  • Janus Kinase 2
  • Male
  • Nerve Regeneration / drug effects
  • Nerve Regeneration / physiology*
  • Peripheral Nerve Injuries*
  • Peripheral Nerves / metabolism
  • Peripheral Nerves / physiopathology
  • Phosphorylation / drug effects
  • Protein Isoforms / drug effects
  • Protein Isoforms / metabolism
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / metabolism
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / metabolism
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Erythropoietin / drug effects
  • Receptors, Erythropoietin / genetics
  • Receptors, Erythropoietin / metabolism*
  • Recombinant Proteins
  • Schwann Cells / drug effects
  • Schwann Cells / metabolism*
  • Sciatic Neuropathy / drug therapy
  • Sciatic Neuropathy / metabolism*
  • Sciatic Neuropathy / physiopathology
  • Up-Regulation / drug effects
  • Up-Regulation / physiology

Substances

  • Protein Isoforms
  • Proto-Oncogene Proteins
  • RNA, Messenger
  • Receptors, Erythropoietin
  • Recombinant Proteins
  • Erythropoietin
  • Protein-Tyrosine Kinases
  • JAK2 protein, human
  • Jak2 protein, rat
  • Janus Kinase 2
  • Extracellular Signal-Regulated MAP Kinases